Instil Bio Stock (NASDAQ:TIL)

Forecast Revenue Ownership Financials Chart

Previous Close

$14.15

52W Range

$6.08 - $14.75

50D Avg

$11.78

200D Avg

$10.55

Market Cap

$92.68M

Avg Vol (3M)

$27.34K

Beta

1.22

Div Yield

-

TIL Company Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

49

IPO Date

Mar 19, 2021

Website

TIL Performance

TIL Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-90.54M	$-226.46M	$-155.56M
Net Income	$-156.09M	$-223.18M	$-156.79M
EBITDA	$-85.78M	$-200.20M	$-155.56M
Basic EPS	$-24.00	$-1.72	$-1.48
Diluted EPS	$-24.00	$-1.72	$-1.48

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
NUVB	Nuvation Bio Inc.
ACHL	Achilles Therapeutics plc
NXTC	NextCure, Inc.
CTMX	CytomX Therapeutics, Inc.
SPRO	Spero Therapeutics, Inc.
ASMB	Assembly Biosciences, Inc.
NLTX	Neurogene Inc.